ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
22.09
-0.08 (-0.36%)
Apr 20, 2026, 4:00 PM EDT - Market closed
ACADIA Pharmaceuticals Employees
As of December 31, 2025, ACADIA Pharmaceuticals had 798 total employees, including 796 full-time and 2 part-time employees. The number of employees increased by 144 or 22.02% compared to the previous year.
Employees
798
Change (1Y)
144
Growth (1Y)
22.02%
Revenue / Employee
$1,342,738
Profits / Employee
$489,975
Market Cap
3.77B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Telix Pharmaceuticals | 1,184 |
| Crinetics Pharmaceuticals | 594 |
| Denali Therapeutics | 503 |
| Travere Therapeutics | 497 |
| Dyne Therapeutics | 258 |
| Structure Therapeutics | 220 |
| Edgewise Therapeutics | 146 |
| Tango Therapeutics | 137 |
ACAD News
- 4 days ago - Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting - Business Wire
- 5 days ago - Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 - Business Wire
- 14 days ago - Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome - Business Wire
- 5 weeks ago - Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Business Wire
- 6 weeks ago - Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors - Business Wire
- 7 weeks ago - Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome - Business Wire
- 7 weeks ago - Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview - Business Wire
- 2 months ago - Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Business Wire